New hope for lung cancer patients when targeted drugs stop working
NCT ID NCT06927986
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This Phase 3 trial tests a new drug called SYS6010 against standard chemotherapy in 380 people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to targeted therapy. The goal is to see if SYS6010 can delay cancer growth better than chemo. Participants are randomly assigned to receive either SYS6010 or a platinum-based chemo combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYS6010
- What this could lead to
- If it works, this could offer a new treatment option for people with EGFR-mutated lung cancer whose current targeted therapy has stopped working.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not yet proven. The drug may not work better than chemotherapy or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China